Group 1 - The company expects to achieve a net profit attributable to shareholders of the parent company between 50 million to 65 million yuan for the year 2025, representing an increase of 20.5755 million to 35.5755 million yuan compared to the same period last year, which translates to a year-on-year growth of 69.93% to 120.9% [1] - The main reasons for the performance change include the company's continuous promotion of refined management and technological upgrades, which further optimized operational efficiency and cost structure [1] - The company has deepened its differentiated competitive strategy and increased market expansion efforts, seizing market opportunities to enhance overall profitability [1]

Core Viewpoint - The company, 圣达生物, expects significant growth in net profit for the year 2025, with projections indicating an increase of 69.93% to 120.90% compared to the previous year [1] Financial Projections - The company anticipates a net profit attributable to shareholders of the parent company to be between 50 million and 65 million yuan for 2025 [1] - The projected net profit, excluding non-recurring gains and losses, is expected to be between 43 million and 58 million yuan, reflecting a year-on-year growth of 91.42% to 158.19% [1] Operational Improvements - The company has enhanced operational efficiency and cost structure through continuous fine management and technological upgrades [1] - A differentiated competitive strategy has been deepened, with increased market expansion efforts to seize market opportunities, contributing to overall profitability improvement [1]

报告期内，公司通过持续推动精细化管理与技术升级，进一步优化了运营效率与成本结构。同时，公司 深化差异化竞争战略，加大市场拓展力度，抓住市场机会，推动了公司整体盈利能力的提升。 圣达生物（603079）(603079.SH)披露2025年年度业绩预增公告，公司预计2025年年度实现归属于母公 司所有者的净利润为5000万元至6500万元，同比增长69.93%至120.90%。预计2025年年度实现归属于母 公司所有者的扣除非经常性损益的净利润为4300万元至5800万元，同比增长91.42%至158.19%。 ...

Core Viewpoint - The company, Shengda Bio (603079.SH), expects a significant increase in net profit for the year 2025, projecting a growth of 69.93% to 120.90% compared to the previous year [1] Financial Performance - The estimated net profit attributable to the owners of the parent company for 2025 is projected to be between 50 million to 65 million yuan [1] - The estimated net profit attributable to the owners of the parent company, excluding non-recurring gains and losses, is expected to be between 43 million to 58 million yuan, reflecting a growth of 91.42% to 158.19% [1] Operational Strategy - The company has improved operational efficiency and cost structure through continuous fine management and technological upgrades [1] - The company has deepened its differentiated competitive strategy and increased market expansion efforts to seize market opportunities, enhancing overall profitability [1]

证券代码：603079 证券简称：圣达生物 公告编号：2026-003 浙江圣达生物药业股份有限公司 关于拟计提资产减值准备的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、本次拟计提资产减值准备情况 二、本次拟计提资产减值准备的具体说明 1、信用减值损失 根据《企业会计准则第22号－金融工具确认和计量》相关规定，公司以预 期信用损失为基础，对应收票据、应收账款、其他应收款等进行减值测试并确 认减值损失。经初步测试，本次拟计提信用减值损失65.00万元。 2、资产减值损失 根据《企业会计准则第1号－存货》和公司相关会计政策，资产负债表日， 存货应当按照成本与可变现净值孰低计量。当存货成本高于其可变现净值的， 应当计提存货跌价准备。计提存货跌价准备后，如果以前减记存货价值的影响 因素已经消失，导致存货的可变现净值高于其账面价值的，在原已计提的存货 跌价准备金额内予以转回，转回的金额计入当期损益。经初步测算，本报告期 公司拟计提资产减值损失850.00万元，为公司存货跌价损失。 三、本次拟计提资产减值准备对公司的影 ...

浙江圣达生物药业股份有限公司 2025年年度业绩预增公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603079 证券简称：圣达生物 公告编号：2026-002 预计2025年年度实现归属于母公司所有者的扣除非经常性损益的净利润 为4,300.00万元至5,800.00万元，与上年同期（法定披露数据）相比，将增加 2,053.59万元至3,553.59万元，同比增长91.42%至158.19%。 重要内容提示： 业绩预告的具体适用情形：实现盈利，且净利润与上年同期相比上升50% 以上。 经浙江圣达生物药业股份有限公司（以下简称"公司"）财务部门初步 测算，预计2025年年度实现归属于母公司所有者的净利润为5,000.00万元至 6,500.00万元，与上年同期（法定披露数据）相比，将增加2,057.55万元至 3,557.55万元，同比增长69.93%至120.90%。 经公司财务部门初步测算，预计2025年年度实现归属于母公司所有者的 扣除非经常性损益的净利润为4,300.00万元至5,800.00万元，与上 ...

Group 1 - The company has successfully completed the EU CEP registration in 2024 and is focusing on global development as a strategic direction for long-term value growth [2] - The company has established a regular export layout for its main products, including vitamins, biological preservatives, and functional ingredients, targeting overseas markets such as Europe [2] - The revenue situation from these exports aligns with the company's overall pace of international expansion, indicating a strategic approach to market development [2] Group 2 - The company employs a flexible and diversified sales strategy, adapting its business operations based on different development stages and customer needs [2]

Group 1 - The company has completed the registration of changes in its business license and has obtained a new business license from the Zhejiang Provincial Market Supervision Administration [2] - The new business license indicates that the registered capital of the company is 189,026,240 yuan, and it is classified as a listed other joint-stock company [2] - The company’s operational scope includes the production of pharmaceuticals, feed additives, food additives, and hazardous chemicals, among other activities [2] Group 2 - The company held meetings on November 27, 2025, and December 15, 2025, to approve the cancellation of the supervisory board and amendments to the company’s articles of association [1] - The company has published relevant announcements regarding these changes in the Shanghai Securities Journal and on the Shanghai Stock Exchange website [1]

浙江圣达生物药业股份有限公司 章 程 二〇二五年十二月 | | | | | | 浙江圣达生物药业股份有限公司章程 第一章 总 则 第一条 为维护浙江圣达生物药业股份有限公司(以下简称"公司"或"本公 司")、股东、职工和债权人的合法权益，规范公司的组织和行为，根据《中华 人民共和国公司法》(以下简称"《公司法》")、《中华人民共和国证券法》(以 下简称"《证券法》")和其他有关规定，制定本章程。 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公司。 公司以发起方式设立，在浙江省市场监督管理局注册登记，统一社会信用代 码：9133100070471153X3。 第三条 公司根据中国共产党的章程规定，设立中国共产党的组织，建立党的工 作机构，配备党务工作人员。党组织机构设置、人员编制纳入公司管理机构和编 制，党组织工作经费纳入公司预算，从公司管理费中列支。党委在公司发挥政治 核心作用。 第四条 公司经中国证券监督管理委员会（以下简称"中国证监会"）核准，首 次向社会公众发行人民币普通股 2,000 万股，并于 2017 年 8 月 23 日在上海证券 交易所上市。 第五条 公司注册名称： 中文全称：浙江 ...

证券代码：603079 证券简称：圣达生物 公告编号：2026-001 浙江圣达生物药业股份有限公司 关于完成工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江圣达生物药业股份有限公司（以下简称"公司"）分别于2025年11月 27日、2025年12月15日召开第四届董事会第二十一次会议及2025年第四次临时 股东大会，审议通过了《关于取消监事会、修改<公司章程>并办理工商变更登 记的议案》、《关于制定、修订公司部分治理制度的议案》。具体内容详见公 司于2025年11月28日和2025年12月26日刊载于《上海证券报》、《证券时报》 及上海证券交易所网站（www.sse.com.cn)的《浙江圣达生物药业股份有限公司 关于取消监事会、修改<公司章程>并办理工商变更登记及制定、修订公司部分 治理制度的公告》（公告编号：2025-062）和《浙江圣达生物药业股份有限公 司2025年第四次临时股东大会决议公告》（公告编号：2025-066）。 近日，公司已完成了《公司章程》备案和工商变更登记等手续，并取得了 浙 ...